Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Islets of Langerhans Clear all
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 12, 2026, 2:49 PM EDT
No Longer Available No phase listed Expanded access

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NCT01309022
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 12, 2026, 2:49 PM EDT
Terminated Not applicable Interventional Results available

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

NCT00730483
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
Interventions
PVA microporous hydrospheres/doxorubicin hydrochloride
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

NCT00027638
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
Interventions
thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 12, 2026, 2:49 PM EDT
Terminated Phase 1 Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
Interventions
indium In 111 pentetreotide
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 12, 2026, 2:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

NCT02846571
View directory record Official record
Conditions
Diabetes
Interventions
Human Pancreatic Islet Transplantation
Biological
Lead sponsor
Midhat H. Abdulreda
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 12, 2026, 2:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus

NCT00590876
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

NCT01169649
View directory record Official record
Conditions
PANCREAS, Neuroendocrine
Interventions
MK-2206
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

NCT00131911
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Neuroendocrine Tumor, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma, WDHA Syndrome
Interventions
sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 12, 2026, 2:49 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

NCT00260234
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Cultured Islet Cells (human); Encapsulated
Biological
Lead sponsor
Novocell
Industry
Eligibility
20 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Not applicable Interventional Results available

Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas

NCT01762059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bi-homonal Bionic Pancreas, Usual care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 12, 2026, 2:49 PM EDT
Not listed No phase listed Observational

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

NCT03415139
View directory record Official record
Conditions
Diabetes Mellitus, Cancer
Interventions
Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 12, 2026, 2:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis

NCT02224898
View directory record Official record
Conditions
Pancreatitis, Chronic
Interventions
Mobile Mindfulness Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients

NCT00285194
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans, hOKT3γ1 (Ala-Ala)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 12, 2026, 2:49 PM EDT
Terminated Phase 3 Interventional Results available

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

NCT00428597
View directory record Official record
Conditions
Carcinoma, Islet Cell, Carcinoma, Pancreas
Interventions
sunitinib malate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Aurora, Colorado • Iowa City, Iowa • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2010 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
Interventions
Bevacizumab, Temsirolimus
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
57
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 12, 2026, 2:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

NCT03746769
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic Human Islet Cells, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 12, 2026, 2:49 PM EDT
Terminated Phase 1Phase 2 Interventional

Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus

NCT00579371
View directory record Official record
Conditions
Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1
Interventions
Islets of Langerhans
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 12, 2026, 2:49 PM EDT
Completed Phase 2 Interventional

Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen

NCT00021801
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet Cell Transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 12, 2026, 2:49 PM EDT
Terminated Phase 2 Interventional Results available

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

NCT00843531
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
RAD001, erlotinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 12, 2026, 2:49 PM EDT
Recruiting No phase listed Observational

The T1D Exchange Registry

NCT04629586
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
Interventions
No intervention
Other
Lead sponsor
T1D Exchange, United States
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 12, 2026, 2:49 PM EDT
Not listed Phase 1 Interventional

UVA Islet Cell Transplantation in Patients With Type I Diabetes

NCT00605592
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Pancreatic Islets of Langerhans Cell Transplant
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2009 · Synced Sep 12, 2026, 2:49 PM EDT